Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.


TSXV:ARCH - Post by User

Post by Arbourmarkon Nov 23, 2021 8:45pm
147 Views
Post# 34159715

Selling

SellingToday was largest volume I have seen in past month and actually first day to see slight change in trading pattern. Generally it opens higher at open as it did today then the same nefarious sellers come in and knock it down through the day and late afternoon walk it up with surge at the last 30 minutes but it failed today.

I feel nothing to be concerned with as they tried but it hit some resistance.

Here is what is very interesting in my opinion, at $5 this stock become margin applicable at 25%. If they uplist to TSX or Nasdaq it immediately qualifies at 50% if over $3.

I see numerous posts outlining key positive point but often left out is Canadian government provided $6.8M towards phase 2, I would not be surprised that Feds foot the bill for Phase 3 100%, saving Arch $50M dilution, that is huge.

62% of stock is held by insiders, do you see them selling? The answer is No, so why would you?

I personally own 500,000 shares so not sure what that is percentage wise, roughly 1% and I am not even close to selling.

This is going much higher, CEO busy lining up university hospitals to participate in phase 3 and chatting up
institutional investors. Priority is TSX and US listing and getting big US Institutional Investors interested. 


<< Previous
Bullboard Posts
Next >>